Amberkar Mohanbabu Vittalrao¹, Saurabh Agarwal², Meena Kumari Kamalkishore^1* and Basavaraj Poojar³

¹Department of Pharmacology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal,Karnataka, India –576104.

²Medical Science Liaison,Sanofi Pasteur India Pvt.Ltd,Dalibagh,Lucknow-226001.

³Basavaraj Poojar-Department of Pharmacology,Kasturba Medical College, Mangaluru, Manipal Academy of Higher Education, Manipal, Karnataka, India-575001.

Corresponding Author E-mail: mini41178@yahoo.co.in

DOI : https://dx.doi.org/10.13005/bpj/1777

Abstract

Depression is a common problem worldwide since the ages. Mostly it is treated with Selective serotonin reuptake inhibitors (SSRI) but they are not effective in each and every patient. Hence other methods for better effective ways to treat depression are needed. This study was divided as acute and chronic study. Each containing five groups control, escitalopram (standard),omega -3 fatty acid (FA),escitalopram + omega -3 FA (2 doses).A 15 min pretest was done followed 24h later by a 5 min test.Various models of depression were used and biochemical analysis was done. In acute study there was no significant potentiation effect seen .In chronic study there was significant potentiation effect of omega 3 FA. Based on the results we conclude omega 3 fatty acid can be considered as a part of therapeutic use along with escitalopram. Further clinical studies may be required to validate the results of this study.

Keywords

Selective serotonin reuptake inhibitor; Forced swimming test; Open-field test; Splash test; depression

Download this article as: 

Copy the following to cite this article: Vittalrao A. M, Agarwal S, Kamalkishore M. K, Poojar B. Evaluation of Potentiation Effect of Omega-3 Fatty Acid on the Antidepressant Efficacy of Escitalopram in Albino Rats. Biomed Pharmacol J 2019;12(3).

Copy the following to cite this URL: Vittalrao A. M, Agarwal S, Kamalkishore M. K, Poojar B. Evaluation of Potentiation Effect of Omega-3 Fatty Acid on the Antidepressant Efficacy of Escitalopram in Albino Rats. Biomed Pharmacol J 2019;12(3).Available from: http://biomedpharmajournal.org/?p=28789

Introduction

Depression is a mental disorder which is common , manifesting with depressed mood, anhedonia, lethargy, feelings of guilt or low self-esteem, disturbed sleep or appetite and poor concentration.It is estimated by the World Health Organisation that depression affects approximately 350 million  people worldwide is associated with increasing morbidity¹.  A recent study has shown that depression is one of the ten leading causes of disabilities  affecting up to 21% of the world population and will be the second leading cause of disability adjusted life years (DALY) by 2020².

It has high impact on social and economic aspect, due to massive decrease in work

productivity and increased usage of health care³.Enhancement of monoaminergic neurotransmisssion is the  current pharmacological treatment of depression  . However, despite its widespread use in clinical practice, it has challenges like onset of action, poor efficacy  and presence of side effects^4,5.Contrary to expectations, existing therapeutic options  are effective in only one-third of depressed patients.Moreover, the time required for its maximal antidepressant activity is approximately 3–4 weeks⁶. Furthermore, single agent does not have more than 30% of remission rates^,7.

Majority of patients have low compliance due to side effects and refuse to take antidepressants in appropriate doses.Therefore, the identification of novel drug or novel treatment combination with drugs that augment the efficacy of antidepressant  is still needed.Role of nutrition has found greater role in depressive disorder as good amount of nutrients are essential for healthy mood^8-10.Nutrients are essential for optimal production of neurotransmitters influencing mood¹¹.There are  reports mentioning lower concentration of Eicosapentaenoic acid(EPA) and Docosahexaenoic acid (DHA) in depressed individuals as compared to non-depressed individuals^12,13.

Meta-analytic reviews^14,15 and several clinical trials^16-19 have  reported an antidepressant effect of Polyunsaturated fatty acids(PUFAs).There is increased evidence from animal as well as human studies showing omega-3 fatty acids may play an etiological role in several inflammatory, autoimmune and neuropsychiatric disorders^20,21.

Hence this study was conducted with an aim to explore the possible effect of omega-3 fatty acids in  depression animal models.

Materials and Method

Animals

Sixty Albino Wistar rats of either sex (from Central animal house,KMC,Manipal) were used in the study. The rats used were 3-4 months old and weight 150–250 gm. Animals were housed in cages and were provided with  pellet diet and water ad libitum throughout the study except during testing. Rats were maintained on a 12 h light (0700–1900 h)-12 h dark cycle at temperature of 25±2◦C and relative controlled humidity. They were allowed to acclimatize for a week before the onset of the experiment. Experiment was conducted in accordance with the Good laboratory practice(GLP) guidelines and  CPCSEA guidelines after obtaining approval from Institutional Animal Ethics Committee  IAEC/KMC/79/2015 dated 25-09-2015.

Drugs

Escitalopram:  10 mg per kg and 5 mg per kg.

Omega-3 Fatty Acid: 500 mg per kg.

Study design

Acute Study

There were total five groups, in each group 6 rats. Drugs were administered for 7 days as follows:

Group 1 (Control) – 2% Gum Acacia orally 23.5 and 1 h before the test.

Group 2 (Escitalopram) –  10 mg/kg   dissolved in 2% Gum acacia orally 23.5 and 1 h before the test.

Group 3 (Omega-3 FA) –  500 mg/kg in 2% Gum acacia orally 2 h before the test.

Group 4 (Escitalopram plus omega-3 FA)- Rats were given omega-3 fatty acids 500 mg/kg orally 2 h before the test and escitalopram dissolved in 2% Gum acacia in a dose of 10 mg/kg orally 23.5 and 1 h before the test.

Group 5 (Escitalopram plus omega-3 FA)-This group test the efficacy and augmentation effect of omega-3 FA with sub therapeutic level of escitalopram. Rats were administered with omega-3 fatty acids 500 mg/kg orally 2 h before the test and escitalopram dissolved in 2% Gum acacia in a dose of 5 mg/kg orally 23.5 and 1 h before the test.

Chronic Study

The schedule of drug administration was similar to acute study omega-3 fatty acids was given  500 mg/kg orally for 28 days prior to the test both alone, as well as in combination with escitalopram. Two hours before the test, the last dose of omega-3 fatty acids was given.

Experiments

Forced swimming test(FST)

Porsolt et al.developed this model for antidepressant activity ²². Rats were made to swim in a  cylinder filled with water upto 30 cm at 25̊C. They were trained for a 15-min pretest swim   followed by a 5-min test swim session next day. After the swim  session, rats were removed from water,  and after 20 min were returned to their cages. After each test,the cylinders were  washed completely. In pretest session, rats are  active.After 2-3 min activity decreases to produce immobility, it keeps its head above water. This  immobility is attenuated by antidepressants. In the test session,the behavior of rats were judged in blocks of 5 s for:  immobility ,swimming & climbing .The experiment was videorecorded and the behavioral scoring was done .

Open-field test

This test was used to assess the ambulatory behavior²³. The instrument consist of a wooden box (40cm×60cm×50cm) ,its floor was divided into 12 equal rectangles. At the initiation of each trial, a rat was placed in the left corner. In a 6 min session,the number of rectangles crossed with all paws were counted. The room was dimly lit to prevent anxiety behavior. In between the tests,the instrument was cleaned with 10% ethanol to avoid bias.

Splash test

This test was performed ten minutes after the open-field test ,²⁴ with minor modifications .Ten percent sucrose solution was applied on the dorsum of a rat placed individually in plexiglass boxes (9×7×11 cm). The sucrose solution dirties the rat fur ,due to its viscosity and  initiates grooming behavior in animals which was recorded for  5 min as an index of self-care and motivational behavior. To hide animal clues,the apparatus was cleaned with 10% ethanol.

Biochemical analysis

After conducting the experiment, rats were sacrified and blood  was used for testing –

Reduced glutathione (GSH) and Malondialdehyde (MDA) levels.

Statistical Analysis

P value <0.05 was taken as significant, one-way ANOVA followed by Tukey’s post-hoc test was used.

Results

Acute Study

Table 1: Effect of escitalopram and omega-3 fatty acid on forced swimming

Group (n=6)	Counts of immobility (Mean±S.E.M)	Counts of swimming (Mean±S.E.M)	Counts of climbing (Mean±S.E.M)
Control	30.00±1.71	19.00±0.73	12.00±0.58
Standard(escitalopram)	23.00±1.06 a	25.00±1.26 a	14.00±0.58
Omega-3 FA	27.00±1.29	20.00±1.06	12.00±0.58
Escitalopram10mg+Omega-3 FA	21.00±0.86 b	24.00±1.06 a	13.00±0.58
Escitalopram 5mg+Omega-3 FA	24.00±0.73 a	24.00±0.73 a	13.00±0.58

^a p<0.05 vs control group,  ^bp<0.001 vs control group.

Table 1 shows the results of forced swimming test done at 1 week. One count is duration of 5 sec. The standard group (escitalopram) showed a significant reduction in the counts of immobility (23.00±1.06, p<0.05) along with a significant increase in the counts of swimming (25.00±1.26, p<0.05) compared to the control group. However, the Omega 3 FA group did not show any significant difference in the counts of immobility, counts of swimming and counts of climbing. The escitalopram 10mg + omega 3 FA group as well as the escitalopram 5mg + omega 3 FA group showed a significant reduction in the counts of immobility (21.00±0.86, p<0.001; 24.00±0.73, p<0.05 respectively) with a significant increase swimming counts in both the groups (24.00±1.06, p<0.05; 24.00±0.73, p<0.05) when compared to the control and escitalopram group. There were no significant increase in climbing counts in any of the groups when compared to control.

Table 2: Effect of escitalopram and omega-3 fatty acid on open field test

Group (n=6)	Number of entries (Mean±S.E.M)
Control	33.50±1.31
Escitalopram	39.50±3.10
Omega-3	29.17±2.73
Escitalopram10mg+omega-3 FA	40.33±2.59
Escitalopram 5mg+omega-3 FA	37.33±1.76

Table 2 shows the results of the open field test done at 1 week. The above results does not show any significant difference in the number of entries in any of the groups when compared with control and the standard treatment group (escitalopram).

Table 3: Effect of escitalopram and omega-3 fatty acid on splash test

Group (n=6)	Time in sec. (Mean±S.E.M)
Control	201.00±5.67
Escitalopram	187.00±4.47
Omega-3 FA	201.33±5.50
Escitalaopram.10mg+omega-3 FA	163.00±3.25 b,c
Escitalopram 5mg+omega-3 FA	174.83±3.27 a

^a p<0.05 versus group control,  ^bp<0.001 versus control,  c- escitalopram 10mg+ omega 3 group compared to escitalopram group;

Table 3 shows the splash test done at 1 week. It indicates that there is a significant difference in the time taken by the escitalopram 10mg+omega 3 FA group and escitalopram 5 mg+ omega 3 group when compared to control (163.00±3.25, p<0.001 and 174.83±3.27, p< 0.05) along with a significant reduction in time taken by the escitalopram 10mg + omega 3 group when compared with the standard treatment group (escitalopram) (163.00±3.25, p<0.05).

Table 4: Effect of escitalopram and omega-3 fatty acid on MDA and GSH

S.No.	Group (n=6)	MDA (Mean±S.E.M)	GSH (Mean±S.E.M)
1.	Control	0.047±0.003	1.141±0.013
2.	Escitalopram	0.041±0.001	1.327±0.015a
3.	Omega-3	0.045±0.003	1.180±0.007
4.	Escitalopram.10mg+omega-3 FA	0.051±0.002	1.525±0.017 a
5.	Escitalopram 5mg+omega-3 FA	0.041±0.002	1.345±0.014 a

^a p<0.05 versus group control

As shown in table 4 ,there was no significant difference among the control group and the test groups p<0.005 with respect to MDA levels. Levels of glutathione reductase at 1 week was significantly more in the escitalopram group (1.327±0.015, p<0.05 and significantly increase in GSH in test groups, escitalopram 10mg+omega-3 (1.525±0.017; p<0.05) and escitalopram 5 mg+omega-3 FA (1.345±0.014; p<0.05) compared to control group

Chronic Study

Table 5: Effect of escitalopram and omega-3 fatty acid on forced swimming test

Group (n=6)	Count of immobility (Mean±S.E.M)	Count of swimming (Mean±S.E.M)	Counts of climbing (Mean±S.E.M)
Control	29.00±0.96	17.00±0.73	12.00±1.06
Escitalopram	21.00±1.43a	26.00±1.06 a	13.50±0.89
Omega-3 FA	25.00±0.89	23.00±0.86	13.00±1.13
Escitalopram 10mg+omega-3 FA	15.00±0.73 a	27.33±1.30 a	14.33±1.20
Escitalopram 5mg+omega-3 FA	17.00±0.58 a	27.00±1.24 a	13.50±0.96

 ^ap<0.001 versus control group

Table 5 shows the results of forced swimming test done at 4th week.  The standard group (escitalopram) showed a significant reduction in the counts of immobility (21.00±1.43, p<0.01) along with a significant increase in the counts of swimming (26.00±1.06, p<0.01) compared to the control group. However, the omega 3 FA group did not show any significant difference in the counts of immobility, counts of swimming and counts of climbing. The escitalopram 10mg + omega 3 group as well as the escitalopram 5mg + omega 3 FA group showed a significant reduction in the counts of immobility (15.00±0.73, p<0.001; 17.00±0.58, p<0.01 respectively) with a significant increase swimming counts in both the groups (27.33±1.30, p<0.05; 27.00±1.24^, p<0.01 respectively) in comparison to the control and escitalopram group. There were no significant increase in climbing counts in any of the groups in comparison to control.

Table 6: Effect of escitalopram and omega-3 fatty acid on open field test

Group (n=6)	Number of entries (Mean±S.E.M)
Control	34.67±1.70
Escitalopram	44.00±1.26 a
Omega-3 FA	41.16±1.90
Escitalopram 10mg+omega-3 FA	47.00±2.67 a
Escitalopram 5mg+omega-3 FA	39.00±2.62

^a– P<0.05 versus control group

Table 6 .The number of entries increased significantly in the standard group escitalopram (44.00±1.26; p<0.05) when compared with control along with significant increase in the number of entries in the escitalopram 10mg+omega-3 FA (47.00±2.67; p<0.05) group when compared to control.

Table 7: Effect of escitalopram and omega-3 fatty acid on splash test

Group (n=6)	Time in secs. (Mean±S.E.M)
Control	210.00±11.94
Escitalopram	182.00±5.46a
Omega-3FA	196.00±4.70
Escitalopram 10mg+omega-3 FA	154.00±2.12b
Escitalopram 5mg+omega-3 FA	168.00±4.03 b

^a p<0.05 vs control group; ^b p<0.001 vs control group

As shown in table 7 there was a significant decrease in time in test groups escitalopram (182.00±5.46; p<0.05), escitalopram 10mg+omega-3 (154.00±2.12; p<0.001) and escitalopram 5mg+omega-3(168.00±4.03; p<0.001) when compared to control.

Table 8: Effect of escitalopram and omega-3 fatty acid on MDA and GSH

Group (n=6)	MDA (Mean±S.E.M)	GSH (Mean±S.E.M)
Control	0.055±0.005	1.242±0.013
Escitalopram	0.048±0.004	1.410±0.014 b
Omega-3 FA	0.068±0.008	1.280±0.007
Escitalopram 10mg+omega-3 FA	0.100±0.003a	1.625±0.017 b
Escitalopram 5mg+omega-3 FA	0.058±0.012	1.445±0.014 b

^a p<0.05 versus control group, ^b p<0.001 versus control group

As shown in table 8 there was significant increase in MDA in the test group escitalopram 10mg+omega-3(0.100±0.003;p<0.05) when compared with the control. There was increase in GSH with a significant difference in the standard groups escitalopram (1.410±0.014; p<0.001). The test groups escitalopram 10mg+omega-3 (1.625±0.017; p<0.001) and ecitalopram 5mg+omega-3(1.445±0.014; p<0.001) also showed a significant increase in GSH when compared to the control group.

Discussion

This study shows that Omega-3 fatty acids possess significant antidepressant efficacy in their combination with escitalopram. The study was divided into 2 parts acute (1 week) and chronic study (4 weeks).The results showed that omega-3 has no effect in short term either alone or in potentiating the escitalopram but in chronic study done over 4 weeks it showed potentiation effect with escitalopram.

The results are consistent with that of previous studies which have reported good efficacy of omega-3 supplementation with antidepressants in uncomplicated MDD.^{17, 25, 26} The present study shows the antidepressant effect of omega-3 fatty acids, and its combination with escitalopram will potentiate the antidepressant efficacy than the standard drug escitalopram alone.

The suggestive possible mechanisms are as follows. Inflammatory processes are linked with depression. Omega-3 fatty acids  has an effect  on brain-derived neurotrophic factor and reduces inflammatory mediators²⁷ .A third mechanism is omega-3 fatty acids maintain membrane integrity and fluidity²⁸ . Role of omega-3 fatty acids in depression with respect to receptor signaling and neurotransmitter levels have been studied in animal models.²⁹

Proinflammatory cytokines lower precursor neurotransmitter levels, activate hypothalamic-pituitary axis, and alter neurotransmitter metabolism in the central nervous system. Increase in these cytokines are associated with severity of depression ³⁰. Different factors such as psychological stress, infection, trauma, allergies, and toxins increase the cytokines. Omega-3 fatty acids are inhibitors of these proinflammatory cytokines, although the precise mechanism is unclear ³¹.

There are literature evidences suggesting antidepressants can promote neurogenesis³². Chronic treatment with omega-3 fatty acids increases brain-derived neurotrophic factor (BDNF), which play a role in the plasticity of adult nervous system ³³. This is brought about by increase in the cyclic AMP (cAMP) signal-transduction which increases of cAMP response element-binding protein (CREB) leading to increase in BDNF . Serum BDNF was found to correlate negatively with the severity of depressive symptoms ^34,35. Bourre ³⁶et al. mentioned that omega- 3 fatty acids are essential central nervous system membrane components ⁴⁹. Any alterations in membrane lipids can alter function due to change in fluidity. Proteins are incorporated into the lipid bilayer and are sensitive to the lipid microenvironment. They act as receptors, enzymes, and transporters ^37-39 For binding of neurotransmitter and for signalling within the cell an optimal fluidity is required ⁴⁰.

Haag ⁴¹ suggested that there are straight carbon chains in saturated fatty acids. Cis-desaturation of a fatty acid results in more curved carbon chain due to insertion of cis-double bonds in the cell membrane there is curling of the hydrophobic ends of the kinked chains which results in incorporation of more space when it is built into cell membrane phospholipids, thereby increasing the fluidity and functionality of the cell membrane⁴².Stress alters the phospholipids of brain membranes thereby decreasing DHA levels ⁴³.

Several studies have shown in mice models which are nutritionally deficient  in omega fatty acids are more vulnerable to develop depression⁴⁴.Omega fatty acids in neuronal membranes can modulate many of the signal transduction mechanisms Different neurotransmitters such as serotonin, catecholamines and acetylcholine interact with members of a heptahelical transmembrane receptor family ⁴⁵. Murphy et al. and Nicholas et al^46,47 have confirmed that omega-3 fatty acids can increase adenylyl cyclase activity, increase cAMP ,this pathway is used by serotonin, adrenergic and dopamine receptors. It is well known in depression there is decreased serotonergic neurotransmission, Omega-3 fatty acids increase the activity of adenyl cyclase and thus facilitate serotonergic transmission. Fluoxetine increases serotonin synaptic concentration, and in combination with omega-3 fatty acids has potentiating effect. SSRIs have various side effects such as anxiety, insomnia, sexual dysfunction, serotonin syndrome etc., which is not seen with omega-3 fatty acids. So combination can reduce side effects as we can lower the dose of SSRI.As a long-term nutritional supplement, the combination of escitalopram and omega-3 fatty acids can decrease the dose and duration of SSRI administered, it may prove beneficial for prevention of depression in susceptible population.Also if used in children antidepressant dose could be lowered in combination with omega -3 fatty acids.

Limitations

As it is a behavioural study ,sample size of rats should have increased in each group, DHA levels were not measured.

Conclusion

We conclude that omega-3 Fatty acid potentiates antidepressant activity in chronic use but not in acute duration.

Acknowledgement

We acknowledge Manipal Academy of Higher Education for their support in conduct of this study.

Conflict of interest

The authors declare no conflicts of interest.

Funding Source

Department of Pharmacology, Kasturba Medical College, Manipal

References

1. Depression Fact Sheet No. 369.World Health Organisation (WHO) 2012. Accesed on September 18^th Available from :http://www.who.int/mediacentre/factsheets/fs369/en/
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause1990– 2020: Global burden of disease study. Lancet 1997; 349:1498–1504.
3. Nemeroff CB. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res 2007;41:189–206.
4. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of Neuron 2002;34:13–25.
5. Wong ML, Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2001;2:343–51.
6. Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE et al. Innovative approaches for the development of antidepressant drugs: current and future strategies. Neuro Rx 2005;2:590–611.
7. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008; 63:424–434.
8. Shim RS, Baltrus P, Ye J, and Rust G. Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005–2008. J Am Board Fam Med 2011; 24: 33-38.
9. Jacka FN, Mykletun A, Berk M, Bjelland I, Tell GS. The association between habitual diet quality and the common mental disorders in community dwelling adults: the Hordaland Health study. Psychosom Med 2011;73: 483–490
10. Le Port A, Gueguen A, Kesse-Guyot E, Melchior M, Lemogne C, et al. Association between Dietary Patterns and Depressive Symptoms Over Time: A 10-Year Follow-Up Study of the GAZEL Cohort. PLoS ONE 2012;7: e51593.
11. Kemper KJ and Shannon S. CAM Therapies to Promote Healthy Moods. Pediat ClinNorth Am 2007;54: 901-926.
12. Ellis FR, Sanders TA. Long chain polyunsaturated fatty acids in endogenousdepression. J Neurol Neurosurg Psychiatry 1977; 40:168-169.
13. Fehily AM, Bowey O, Ellis FR, Meade BW. Plasma anderythrocyte membranelong chain polyunsaturated fatty acids in endogenous depression. Neurochem Int1981; 5: 37-42.
14. Appleton KM, Rogers PJ and Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressedmood. Am J Clin Nutr 2010;91: 757-70.
15. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trialsof antidepressant efficacy of omega-3 fatty acids.J Clin Psychiatry 2007; 68:1056–1061.
16. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder.A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:267–271.
17. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002; 159:477–479.
18. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolardepression:randomised double-blind placebo controlled study. Br J Psychiatry 2006; 188: 46–50.
19. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH: Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 2006; 163:1098–1100.
20. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. JAm Coll Nutr 2002; 21:495-505.
21. Young G, Conquer J. Omega-3 fatty acids and neuropsychiatricdisorders. Reprod Nutr Dev 2005; 45:1-28.
22. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for Arch Int Pharmacodyn Ther 1977;229:327–36.
23. Hall C,Ballachey EL. A study of the rat’s behavior in a field: A contribution to method in comparative psychology. University of California Publications in Psychology 1932;6:112.
24. Isingrini E, Camus V, Le Guisquet AM, Pingaud M, Devers S, Belzung C. Association between repeated unpredictable chronic mild stress (UCMS) procedures with a high fat diet: a model of  fluoxetine resistance in mice. PLoS ONE 2010;5:e10404.
25. Gertsik L, Poland RE, Bresee C, Rapaport MH. Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients with Major Depressive Disorder. Journal of Clinical Psychopharmacology 2012;32:61-64.
26. Lespérance F, Frasure SN, André E, Turecki G, Lespérance P, Wisniewski SR. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry 2011; 72:1054-62.
27. Ikemoto A, Nitta A, Furukawa S, et al. Dietary n-3 fatty acid deficiency decreases nerve growthfactor content in rat hippocampus. Neurosci Lett 2000; 285:99–102
28. Yehuda S, Rabinovitz S, Carasso RL, et al. Fatty acids and brain peptides. Peptides 1998;19:407–419
29. Logan AC. Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. Altern Med Rev 2003; 8:410–425.
30. Suarez EC. C-reactive protein is associated with psychological risk factors of cardiovascular disease in apparently healthy adults. Psychosom Med 2004 ;66:684-91.
31. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000;71:343-348.
32. Rajkowska G, Miguel-HJJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC et al. Morphometric evidence for neuronal and glial prefrontal cell    pathology in major depression. Biol. Psychiatry 1999;45:1085-1098.
33. Ikemoto A, Nitta A, Furukawa S, Ohishi M, Nakamura A, Fujii Y et al. Dietaryn-3 fatty acid deficiency decreases nerve growth factor content in rat hippocampus. Neurosci. Lett 2000;285:99-102.
34. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C et al.. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressant. Biol. Psychiatry 2003;54:70-75.
35. Molteni R, Barnard RJ, Ying Z, Roberts CK, Gomez-Pinilla F. A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 2002;112:803-814.
36. Bourre JM, Dumont O, Piciotti M, Clément M, Chaudière J, Bonneil M, Nalbone G, Lafont H, Pascal G, Durand G. Essentiality of ω3 fatty acids for brain structure and function1. Health Effects of Omega 3 Polyunsaturated Fatty Acids in Seafoods.World Rev Nutr Diet 1991;66:103-117.
37. Brenner RR. Effect of unsaturated acids on membrane structure and enzyme kinetics. Prog Lipid Res 1984;23:69-96.
38. Spector AA, Yorek MA. Membrane lipid composition and cellular function. J Lipid Res 1985;26:1015-35.
39. Bourre JM, Bonneil M, Clement M, Dumont O, Durand G, Lafont H et al. Function of dietary polyunsaturated fatty acids in the nervous system. Prostaglandins Leukot Essent Fatty Acids 1993;48:5-15.
40. Fernstrom JD. Effects of dietary polyunsaturated fatty acids on neuronal function. Lipids 1999;34:161-169.
41. Haag M. Essential fatty acids and the brain. Can J Psychiatry. 2003;3:195-203.
42. Heron DS, Shinitzky M, Hershkowitz M, Samuel D. Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Proc. Natl. Acad.Sci.USA 1980;77:7463-7467.
43. Hennebelle M, Balasse L, Latour A,  Champeil-Potokar G, Denis S, Lavialle M, Gisquet-Verrier P,  Denis I, Vancasse S.Influence of Omega-3 Fatty Acid Status on the Way Rats Adapt to Chronic Restraint Stress . PloS one 2012 ;  7 (7): e42142
44. Larrieu T and Layé S . Food for Mood: Relevance of Nutritional Omega-3 Fatty Acids for Depression and Anxiety. Front. Physiol.2018; 9:1047
45. Lakhwani LA, Tongia SK, Pal VS, Agrawal RP, Nyati PR, Phadnis PR. Omega-3 fatty acids have antidepressant activity in forced swimming test in Wistar rats. Acta Pol Pharm 2007;64:271-6.
46. Murphy MG. Membrane fatty acids, lipid peroxidation and adenylate cyclase activity in cultured neural cells. Biochem . Biophys.Res. Commun 1985;132:757-63.
47. Nicolas C, Lacasa D, Giudicelli Y, Demarne Y, Agli B, Lecourtier MJ, Lhuillery C.Dietary (n-6) polyunsaturated fatty acids affect beta-adrenergic receptor binding and adenylate cyclase activity in pig adipocyte plasma membrane. J Nutr 1991;121:1179-1186.

(Visited 3,053 times, 1 visits today)